Table 1.
Clinical characteristics of 165 patients with atopic dermatitis and treated with dupilumab
| Variable | Value n (%) |
|---|---|
| Age (years) | 43.35 ± 18.96 |
| Sex, female | 70 (42.42) |
| AD pattern | |
| Persistent | 94/165 (56.96) |
| Late onset (≥ 18 years) | 71/165 (43.04) |
| Clinical scores at baseline | |
| EASI score | 28.84 ± 6.4 |
| Peak score on NRS for pruritus | 8.63 ± 1.67 |
| Peak score on NRS for sleep | 6.42 ± 3.15 |
| DLQI | 22.93 ± 6.24 |
| Atopic comorbidities | |
| Rhinitis | 36/165 (21.81) |
| Asthma | 22/165 (13.33) |
| Conjunctivitis | 18/165 (10.90) |
| Food allergy | 6/165 (3.63) |
| Non-atopic comorbidities | |
| Hypertension and cardiovascular disorders | 24/165 (14.54) |
| Hyperlipidaemia | 20/165 (12.12) |
| Psychiatric/psychological disorders | 11/165 (6.66) |
| Diabetes | 6/165 (3.63) |
| Obesity | 2/165 (1.21) |
| Previous systemic treatments for AD | |
| Cyclosporine A (CsA) | 109/165 (66.06) |
| Systemic corticosteroids | 126/165 (76.36) |
| Phototherapy | 62/165 (37.57) |
| Methotrexate | 4/164 (2.42) |
| Azathioprine | 1/165 (0.60) |